{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:51:52Z","timestamp":1787017912811,"version":"build-2736575974"},"reference-count":18,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Haematol"],"published-print":{"date-parts":[[2016]]},"abstract":"<b><i>Objective:<\/i><\/b> Adherence to tyrosine kinase inhibitor treatment is a significant factor in the achievement of a good clinical response in chronic myeloid leukemia (CML). The aim of this retrospective study is to investigate 1- and 2-year medication adherence to imatinib treatment, linking adherence rates with the clinical outcome, in accordance with European LeukemiaNet Recommendations for the management of CML. We have tried to find a cutoff value for adherence in order to achieve a good clinical outcome. <b><i>Methods:<\/i><\/b> The method used to calculate medication adherence was the ratio between the received and the prescribed daily dose. <b><i>Results:<\/i><\/b> We observed the levels of mean adherence for each of the following response groups (in years 1 and 2, respectively): complete response (0.96, 0.95), MR4.5 (1.00, -), MR4 (0.93, 0.91), major molecular responses (0.96, 0.97), warning (0.91, 0.89) and failure (0.79, 0.84). <b><i>Conclusion:<\/i><\/b> Results show that the higher the adherence, the lower the level of BCR-ABL1. Furthermore, using cutoffs \u22650.9, outcomes were significantly improved compared to those with cutoffs <0.90. This value of adherence is in line with previous publications.<\/jats:p>","DOI":"10.1159\/000444626","type":"journal-article","created":{"date-parts":[[2016,5,9]],"date-time":"2016-05-09T17:05:34Z","timestamp":1462813534000},"page":"45-51","source":"Crossref","is-referenced-by-count":20,"title":["Medication Adherence to Tyrosine Kinase Inhibitors: 2-Year Analysis of Medication Adherence to Imatinib Treatment for Chronic Myeloid Leukemia and Correlation with the Depth of Molecular Response"],"prefix":"10.1159","volume":"136","author":[{"given":"Fiorenzo","family":"Santoleri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruggero","family":"Lasala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ranucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"La Barba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Di Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Vetr\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Di Bartolomeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Costantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2016,5,10]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S92125"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2314-2"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/nm0596-561"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2574"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.2015.1031217"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.36"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050100"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2007.01630.x"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25027"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0056813"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2174\/157488411796151110"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp070035"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2006.00139.x"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(99)80026-5"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3087"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-196543"}],"container-title":["Acta Haematologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/444626","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/444626","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T13:49:09Z","timestamp":1745416149000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000444626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,6,9]]}},"URL":"https:\/\/doi.org\/10.1159\/000444626","archive":["Portico"],"relation":{},"ISSN":["0001-5792","1421-9662"],"issn-type":[{"value":"0001-5792","type":"print"},{"value":"1421-9662","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}